Delaware Court Ruling Boosts MannKind (MNKD) Outlook Amid Liquidia Patent Dispute
A recent Delaware court ruling found Liquidia's Yutrepia infringes on United Therapeutics' patent, a decision expected to positively impact MannKind Corp (MNKD) due to increased royalty income from Tyvaso DPI. Truist maintained a Buy rating on MNKD with a $6 price target, citing strengthened prospects. Despite potential undervaluation based on its Price-to-Sales ratio and a GF Value™ of $7.53, MNKD exhibits mixed fundamentals with strong growth and momentum but weak financial strength and ongoing unprofitability, leading to cautious investor sentiment.
MNKD Stock Draws Trader Focus On Rose Pharma GLP-1 Deal
MannKind Corporation's stock (MNKD) rose over 11% due to a new licensing deal with Rose Pharma for a GLP-1 weight management drug using MannKind's Technosphere platform. The agreement grants MannKind equity, royalties, and a board seat, with Rose Pharma funding later-stage development. This asset-light model provides MannKind with leveraged upside in the growing obesity and IBS pain markets while limiting its financial risk.
Steven Binder sells $128,477 of MannKind (MNKD) stock
Steven Binder, a director at MannKind Corp (MNKD), recently sold 39,051 shares of common stock for $128,477, executed under a Rule 10b5-1 trading plan established in December 2025. Following the sale, Binder retains 713,258 shares. The company has also seen positive developments including FDA approvals, product launches, and favorable analyst ratings, despite Binder's stock sale.
Director Steven Binder Sells 39,051 Shares of MannKind Corp (MNK
Director Steven Binder sold 39,051 shares of MannKind Corp (MNKD) on September 25, 2026, adding to a pattern of insider selling over the past year. Despite the stock trading at a significant discount to its GF Value, categorized as a "Possible Value Trap," the consistent insider selling and mixed guru ownership trends suggest caution for investors. MannKind Corp is a biopharmaceutical company known for its inhaled therapeutic products like Afrezza.
Steven Binder sells $128,477 of MannKind (MNKD) stock By Investing.com
Steven B. Binder, a director at MannKind Corp (NASDAQ:MNKD), sold 39,051 shares of the company's common stock for $128,477 on September 25, 2026, as part of a Rule 10b5-1 trading plan. Following the sale, Binder directly holds 713,258 shares. The stock, currently trading at $3.35, is down 49% from its 52-week high but has surged nearly 47% in the past six months, with InvestingPro analysis suggesting it is undervalued.
Steven Binder sells $128,477 of MannKind (MNKD) stock By Investing.com
Steven Binder, a director at MannKind Corp (NASDAQ:MNKD), sold 39,051 shares of common stock for $128,477 on September 25, 2026, through a pre-established trading plan. Following the sale, Binder directly holds 713,258 shares. The company recently reported strong Q2 revenue and received FDA approvals, with analysts maintaining positive ratings.
Form 4 MannKind Corp For: 28 September By Investing.com
This article announces the filing of Form 4 for MannKind Corp (MNKD) pertaining to September 28. It is a brief report from Investing.com, providing information on an insider trading disclosure without further details within the article itself. The publication time is listed as September 29, 2026, at 01:50 UTC.
Shares valued at $128,478 are proposed for sale by MannKind (MNKD) director Steven Binder.
MannKind Corporation director Steven Binder has filed a notice to sell 39,051 common shares, valued at $128,477.79, with an approximate sale date of September 25, 2026. The shares were acquired through performance stock units on July 15, 2026. The filing also details three prior 10b5-1 sales by Binder in July, August, and September 2026, totaling significant gross proceeds.
MannKind Corporation (MNKD) Options Chain - Yahoo Finance
This article provides the options chain data for MannKind Corporation (MNKD) on Yahoo Finance. It displays real-time stock prices, after-hours trading information, and detailed options data including strike prices, last trade dates, bid/ask prices, and implied volatility for both calls and puts. However, the options chain currently shows no available calls or puts.
MannKind Sees Early ReadyFlow Demand as Pediatric Afrezza Launch Gains Momentum
MannKind (NASDAQ: MNKD) is experiencing strong early demand for its newly launched FUROSCIX ReadyFlow autoinjector, with physician interest expanding beyond previous prescribers. The company's pediatric Afrezza launch is also gaining momentum, targeting a concentrated network of endocrinologists with a bridge program to aid patient access. Additionally, MannKind's MNKD-201, a treatment for idiopathic pulmonary fibrosis (IPF), is progressing towards Phase 2, showing promising tolerability in earlier trials.
MannKind director Steven Binder sells $127,855 in company stock
MannKind director Steven Binder sold 33,558 shares of the company's common stock for $127,855 on September 10, 2026, as part of a pre-established trading plan. Following the sale, Binder still directly holds 752,309 shares. Despite a recent dip, MannKind's stock is up 35% over six months and is considered undervalued by InvestingPro analysis, with recent positive news including FDA approvals and strong Q2 revenue.
MannKind director Steven Binder sells $127,855 in company stock By Investing.com
Steven B. Binder, a director at MannKind Corp. (NASDAQ:MNKD), sold 33,558 shares of company stock for $127,855 on September 10, 2026, as part of a pre-established trading plan. This transaction leaves him with 752,309 shares, while the stock is currently trading at $3.75, which InvestingPro analysis suggests is undervalued with a fair value of $4.04. The sale follows MannKind's strong second-quarter revenue, FDA approvals for new products, and positive analyst ratings.
Cantor Fitzgerald reiterates Overweight rating on MannKind stock
Cantor Fitzgerald has reiterated its Overweight rating and an $8.00 price target for MannKind Corporation (NASDAQ: MNKD), citing the company's strong opportunity in idiopathic pulmonary fibrosis (IPF) with three programs underway. Despite unprofitability in the past year, analysts predict MannKind will achieve profitability this year. The company has also seen recent successes with positive Phase 1b data for inhaled nintedanib, FDA approval for the Furoscix autoinjector, and exceeding Q2 revenue expectations.
A rapid-acting, short-duration inhaled treatment is being developed for weight management
MannKind and Rose Pharma Inc. have entered a licensing and collaboration agreement to develop ROSE-010 Technosphere, an inhaled, rapid-acting, short-duration GLP-1 for weight management. MannKind will license its Technosphere platform to Rose Pharma and provide development support through Phase 1b, receiving equity, royalties, and a board seat in return. ROSE-010, also showing potential for irritable bowel syndrome, aims to offer a flexible and patient-controlled approach to weight management.
Breathing In GLP-1: MannKind Partners With Rose Pharma for Inhaled Weight Management Molecule
MannKind Corporation shares are trading lower after announcing a licensing and collaboration agreement with Rose Pharma. The partnership focuses on developing an inhaled, rapid-acting GLP-1 receptor agonist for weight management, combining Rose Pharma's molecule with MannKind's Technosphere inhalation technology. MannKind will receive an equity interest and potential royalties, supporting the development through Phase 1b.
MannKind (NASDAQ: MNKD) director lines up more stock sales under trading plan
MannKind director Steven Binder has filed a Rule 144 notice to sell up to 33,558 shares of MannKind common stock, valued at $132,218.52, which are related to restricted stock units acquired on July 15, 2026. This planned sale follows earlier Rule 10b5-1 plan sales by Binder in July and August 2026. The filing indicates a neutral impact and sentiment on the company's stock.
MannKind to Present at Upcoming Investor Conferences
MannKind Corporation announced that its management team will present at two upcoming investor conferences: the Cantor Global Healthcare Conference on September 10, 2026, and the H.C. Wainwright 28th Annual Global Investment Conference on September 15, 2026. Live audio webcasts and recorded versions of these presentations will be available on MannKind's investor relations website. The company specializes in biopharmaceutical solutions for chronic cardiometabolic and orphan lung diseases.
MannKind to Present at Upcoming Investor Conferences
MannKind Corporation (Nasdaq: MNKD) announced its management team will present at two upcoming investor conferences: the Cantor Global Healthcare Conference on September 10, 2026, and the H.C. Wainwright 28th Annual Global Investment Conference on September 15, 2026. Live audio webcasts and recorded versions of these presentations will be available on the company's investor relations website. MannKind is a biopharmaceutical company focused on innovative solutions for chronic cardiometabolic and orphan lung diseases.
MannKind to Present at Upcoming Investor Conferences
MannKind Corporation announced that its management team will present at two upcoming investor conferences: the Cantor Global Healthcare Conference on September 10, 2026, and the H.C. Wainwright 28th Annual Global Investment Conference on September 15, 2026. Live audio webcasts of these presentations will be available on MannKind's investor relations website, with recorded versions accessible for 90 days afterward. MannKind is a biopharmaceutical company focusing on cardiometabolic and orphan lung diseases.
MannKind (MNKD) Could Be 48% Undervalued Following Its Afrezza And Pipeline Narrative
MannKind (MNKD) stock is considered 48% undervalued with a fair value estimated at $7.59 per share, significantly higher than its recent $3.95 close. This valuation is based on the projected growth of Afrezza through international expansion and a broadened salesforce, coupled with the progress of its late-stage pipeline programs for respiratory diseases. Despite recent underperformance, the company's future revenue growth and potential for expanded product offerings support the undervalued narrative, though risks like Afrezza's limited market adoption persist.
MannKind Corporation Submits Prospectus Supplement with Legal Opinion on Common Stock Offering
MannKind Corporation (NASDAQ: MNKD) has submitted a prospectus supplement to its automatic shelf registration statement, which includes a legal opinion from Cooley LLP validating the legality of its common stock issuance and sale. This filing was made with the SEC on August 21, 2026, and confirms that MannKind's common stock is traded on NASDAQ. The report also clarifies that MannKind does not qualify as an emerging growth company.
MannKind files legal opinion for common stock offering under shelf registration
MannKind (MNKD) has filed a prospectus supplement and submitted a legal opinion from Cooley LLP regarding the issuance and sale of common stock under its existing automatic shelf registration on Form S-3. This action facilitates the company's ability to offer and sell common stock in the future. The legal opinion is attached as Exhibit 5.1 to a Current Report on Form 8-K.
MannKind (NASDAQ: MNKD) resale taps $0.01 warrant shares
MannKind Corporation (NASDAQ: MNKD) has registered for resale up to 12.85 million shares of common stock by existing selling stockholders. This includes 10.44 million issued shares and 2.41 million shares issuable upon the exercise of pre-funded warrants from a July 24, 2026 private placement, where common shares were sold at $3.89 and pre-funded warrants at $3.88 with a $0.01 exercise price. MannKind will not receive proceeds from this resale but will cover registration expenses, and the selling stockholders may use various methods for disposal.
How MannKind’s (MNKD) Rising Revenue but Renewed Losses Could Reshape Its Growth Investment Story
MannKind Corporation recently reported rising second-quarter 2026 revenue to US$109.37 million, but also a shift from profit to a net loss of US$19.03 million. This return to losses, despite higher revenue, highlights pressure from the company's cost base. The article suggests that while the Technosphere platform and programs like Afrezza and INFLO 1 data for nintedanib DPI offer potential, increasing R&D and commercial costs remain a significant risk to future profitability.
Research Analysts Set Expectations for MannKind Q3 Earnings
HC Wainwright has lowered its Q3 2026 EPS estimate for MannKind to a loss of $0.10, and also reduced full-year estimates through 2030, citing weaker near-term profitability. Despite these revisions, analyst sentiment for MannKind remains largely positive with a consensus "Moderate Buy" rating and a $9.22 target price. The biopharmaceutical company's shares opened down 3.1%, and a director recently sold a significant number of shares.
Rubric Capital discloses 5.83% MannKind Corporation (MNKD) stake
Rubric Capital Management LP and David Rosen have reported a passive ownership stake of 5.83% in MannKind Corporation (MNKD), holding 18,000,000 shares with shared voting and dispositive power. This percentage is based on 308,950,166 shares outstanding as of April 24, 2026. Rubric Capital Master Fund LP is noted as having the right to receive dividends and sale proceeds from over 5% of the common stock.
MannKind FY2029 EPS Estimate Decreased by HC Wainwright
HC Wainwright has reduced its FY2029 EPS estimate for MannKind (NASDAQ:MNKD) to $0.27 from $0.39, while maintaining a "Buy" rating. Despite this revision, the biopharmaceutical company holds a "Moderate Buy" consensus rating from analysts, with an average price target of $9.22. MannKind shares opened at $3.85, and institutional investors own nearly half of the stock.
Is MannKind (MNKD) Undervalued After Positive INFLO 1 Data For Its IPF Pipeline?
MannKind (MNKD) has seen increased investor interest following positive Phase 1b INFLO-1 data for its inhaled nintedanib therapy, leading to a recent stock price jump. Despite short-term momentum, the stock remains down year-to-date and over a three-year period. A widely followed narrative suggests MannKind is undervalued with a fair value of $7.59, driven by Afrezza's growth and pipeline potential, although execution risks exist.
Mannkind director Steven Binder sells $158,547 in common stock
Steven B. Binder, a director at MannKind Corp, sold 39,051 shares of common stock for $158,547 on August 7, 2026, at an average price of $4.06 per share. This sale was conducted via a Rule 10B5-1 trading plan established in December 2025. Despite recent losses, analysts forecast positive earnings and strong revenue growth for MannKind, supported by its expanding product portfolio and recent FDA approvals.
Mannkind director Steven Binder sells $158,547 in common stock By Investing.com
Mannkind director Steven B. Binder sold 39,051 shares of the company's common stock for a total of $158,547 on August 7, 2026, as part of a Rule 10B5-1 trading plan. Despite a recent loss per share, analysts predict positive earnings for fiscal 2026 with strong revenue growth. Recent reports show MannKind Corp. surpassed revenue expectations and received a reiterated Buy rating from H.C. Wainwright due to FDA approvals and promising clinical data.
Mannkind director Steven Binder sells $158,547 in common stock By Investing.com
Steven B. Binder, a director at MannKind Corp (NASDAQ:MNKD), sold 39,051 shares of common stock for $158,547 on August 7, 2026, as part of a Rule 10B5-1 trading plan. Following the sale, Binder directly holds 785,867 shares. Despite a recent loss per share, analysts predict positive earnings for fiscal 2026, supported by strong revenue growth and recent FDA approvals for the company's products.
MannKind Corp (MNKD) Director Steven Binder Sells 39,051 Shares
MannKind Corp Director Steven Binder sold 39,051 shares of MNKD on August 7, 2026, for approximately $158,547, increasing his total sales over the past year to 108,476 shares. This insider selling trend, with 12 sells against 1 buy, contrasts with institutional activity where 4 out of 5 gurus increased their holdings. GuruFocus rates MNKD as a "Possible Value Trap, Think Twice" given its price-to-GF-Value ratio of 0.55, suggesting caution despite its apparent undervaluation.
Sei Investments Co. Buys 253,537 Shares of MannKind Corporation $MNKD
Sei Investments Co. significantly increased its stake in MannKind Corporation (NASDAQ:MNKD) by 53.6% in the first quarter, purchasing an additional 253,537 shares, bringing its total holdings to 726,396 shares valued at approximately $1.78 million. Institutional investors collectively own 49.55% of MannKind, a biopharmaceutical company focused on inhaled therapeutic products. Despite recent positive institutional activity, the stock trades at a negative price-to-earnings ratio, and while analysts maintain a "Moderate Buy" consensus, several have recently reduced their price targets.
First Trust Advisors LP Raises Stake in MannKind Corporation $MNKD
First Trust Advisors LP significantly increased its stake in MannKind Corporation (NASDAQ:MNKD) by 48% in the first quarter, now owning 869,254 shares valued at $2.13 million. Despite institutional investors holding 49.55% of the company, MannKind recently missed earnings expectations with a loss of $0.05 per share and revenue of $90.17 million. Analysts hold a "Moderate Buy" consensus with an average price target of $9.22, significantly above the current stock price of $4.11, although some ratings were mixed.
MannKind (NASDAQ:MNKD) Rating Lowered to Sell at Wall Street Zen
Wall Street Zen downgraded MannKind (NASDAQ:MNKD) from "hold" to "sell," despite a broader analyst consensus of "Moderate Buy" with an average price target of $9.22. The biopharmaceutical company's shares opened at $4.11, up 5.7%, but reported a Q1 loss of $0.05 per share and revenue of $90.17 million, both missing analyst expectations. Institutional investors own nearly half of MannKind's stock, with Vanguard and State Street increasing their positions, while a director recently sold shares to cover tax obligations.
MannKind (MNKD) insider Steven Binder plans 39,051-share Rule 144 stock sale
MannKind Corporation insider Steven Binder plans to sell up to 39,051 common shares under Rule 144 through Morgan Stanley Smith Barney LLC. This filing also discloses previous 10b5-1 plan sales by Binder, including 52,485 shares on July 17, 2026, and 16,940 shares on May 12, 2026. The planned sale involves shares associated with Performance Stock Units.
MannKind Corp Q2 2026: Revenue $109.4M, EPS $(0.06) — 10-Q Summary
MannKind Corp reported its second-quarter 2026 results, showing a significant increase in revenue to $109.4M, up from $76.5M in the prior year, primarily due to the acquisition of scPharma and the addition of Furoscix. Despite revenue growth, the company recorded a net loss of $(19.0)M and diluted EPS of $(0.06) for the quarter. Key business developments included FDA approval for Afrezza's expanded label and Furoscix ReadyFlow autoinjector, alongside progress in their pipeline with MNKD-201 and MNKD-701.
MannKind's Diversified Portfolio Seen Leading to Higher Revenue in H2, Wedbush Says
Wedbush analysts anticipate higher revenue for MannKind in the second half of the year due to its increasingly diversified portfolio. The company's focus for 2026 is on commercial and clinical execution, with Furoscix therapy being a key priority.
MannKind Reports Second Quarter 2026 Financial Results and Provides Business Update
MannKind Corporation reported strong Q2 2026 financial results with total revenues of $109.4 million, a 43% increase year-over-year. The company highlighted three major catalysts for future growth: the launch of Afrezza's pediatric indication, FDA approval of the Furoscix ReadyFlow™ autoinjector, and positive Phase 1b data for nintedanib DPI. These achievements are expected to fuel near-term growth and validate MannKind's diversification strategy.
MannKind Reports Second Quarter 2026 Financial Results and Provides Business Update
MannKind Corporation announced its Q2 2026 financial results, reporting total revenues of $109.4 million, a 43% increase year-over-year. The company highlighted three major catalysts: FDA approval for Afrezza's pediatric indication, FDA approval for FUROSCIX ReadyFlow autoinjector, and positive Phase 1b data for nintedanib DPI. These achievements are expected to drive future growth in its cardiometabolic and orphan lung disease portfolios.
MannKind earnings in focus after FUROSCIX ReadyFlow approval
MannKind Corp is set to release its second-quarter earnings, with analysts anticipating a loss of 1 cent per share on revenue of $109.02 million, reflecting a significant year-over-year increase. The biopharmaceutical company is expected to capitalize on the recent FDA approval of FUROSCIX ReadyFlow, which analysts believe could be transformative for its revenue growth. Investors will be keenly watching for management commentary on the launch trajectory of ReadyFlow and updates on its dry powder inhaler pipeline.
MannKind Q2 2026 Earnings: Revenue Rises 43% as Costs Drive a Net Loss
MannKind Corporation reported a 43% increase in Q2 2026 revenue, reaching $109.4 million, primarily due to the acquisition of scPharma and increased collaboration income. However, the company experienced a net loss of $19.0 million, an adverse swing from a profit of $0.7 million in Q2 2025, driven by higher launch spending for Furoscix and pediatric Afrezza, increased R&D, and significant financing costs. Key approvals for pediatric Afrezza and Furoscix ReadyFlow are expected to expand commercial opportunities, but investors are monitoring launch execution, margin pressures, and pipeline progress.
MNKD Stock Jumps On Receiving FDA Approval For Afrezza To Treat Diabetes In Children
MannKind Corporation's (MNKD) stock gained about 5% after the FDA approved its Afrezza Inhalation Powder for children and adolescents aged 6 and older with type 1 and type 2 diabetes. This makes Afrezza the first and only needle-free, inhaled mealtime insulin available for pediatric patients, who previously relied on injections or pumps. The approval was supported by positive data from the Phase 3 INHALE-1 study, demonstrating Afrezza's efficacy and patient satisfaction compared to traditional methods.
MannKind Corp (MNKD) Financial Health: Profitability & Balance Sheet Analysis
MannKind Corp (MNKD) has a current financial score of 7.90, ranking 72 out of 384 in its industry, indicating weak financial status but high operating efficiency. The company recently reported a quarterly revenue of $90.17 million, marking a 15.08% year-over-year increase, and its net profit surged by 226.30% year-over-year. While key financial metrics like cash and equivalents, total assets, liabilities, and free cash flow are mentioned, the specific data values for these categories have not yet been disclosed by the company.
Vanguard Capital Management (MNKD) discloses 15.45M-share, 5% MannKind position
Vanguard Capital Management LLC and its affiliates have reported a passive 5% ownership stake in MannKind Corp (MNKD), holding 15,450,421 shares as of June 30, 2026. This disclosure was made via a Schedule 13G filing, indicating Vanguard's sole voting power over 2,281,029 shares and sole dispositive power over all its MannKind holdings. The investment is spread across various Vanguard funds and managed accounts, with no single underlying investor holding more than 5% through these positions.
MannKind stock reiterated at Buy by H.C. Wainwright on trial data
H.C. Wainwright has reiterated a Buy rating and a $10.00 price target for MannKind (NASDAQ:MNKD) after positive INFLO-1 trial data for its nintedanib dry powder inhaler. The trial showed good tolerability with no severe adverse events. This news comes alongside recent FDA approvals for MannKind's FUROSCIX ReadyFlow and Afrezza Inhalation Powder, which are expected to contribute to the company's profitability this year.
MannKind stock reiterated at Buy by H.C. Wainwright on trial data
H.C. Wainwright reiterated a Buy rating and a $10.00 price target for MannKind (NASDAQ:MNKD) after positive results from the INFLO-1 trial for its nintedanib dry powder inhaler. The trial showed good tolerability with no severe adverse effects, supporting the drug's development for idiopathic pulmonary fibrosis. The firm also highlighted recent FDA approvals for FUROSCIX ReadyFlow and expanded use of Afrezza, alongside an upcoming PDUFA date, as significant catalysts for MannKind's growth.
MNKD|MannKind Corp|Price:4.115|Chg%:+0.265
This analysis of MannKind Corp (MNKD) by TradingKey highlights its strong fundamentals, high growth potential, and fair valuation within the Biotechnology & Medical Research industry. Despite recent weak stock market performance, the company shows significant institutional ownership and positive analyst ratings with a high price target. The stock is currently trading sideways, suggesting suitability for range-bound swing trading.
MNKD: Phase I-B data show nintedanib DPI is safe and well-tolerated in IPF, enabling phase II advancement
MannKind Corporation (MNKD) announced positive Phase I-B results for its nintedanib Dry Powder Inhaler (DPI) in Idiopathic Pulmonary Fibrosis (IPF) patients. The study demonstrated strong safety and tolerability, with no serious adverse events and effective lung delivery, paving the way for a global Phase II trial. This advancement supports the evaluation of nintedanib DPI as both monotherapy and in combination treatments for IPF.
MannKind’s Inhaled Nintedanib Passes Safety Test in IPF Patients, Paving Way for Global Phase 2 Trial
MannKind's inhaled nintedanib therapy for Idiopathic Pulmonary Fibrosis (IPF) successfully cleared a Phase 1b safety study, demonstrating no serious adverse events or significant gastrointestinal side effects in 27 patients. This positive outcome, building on earlier healthy volunteer data, paves the way for a global Phase 2 trial. The company aims to provide an alternative to oral nintedanib, which is often limited by systemic side effects, by delivering the drug directly to the lungs, potentially reducing adverse reactions like cough.
